However, there are limited data on the efficacy and survival outcomes of the FinHer regimen in the neoadjuvant setting for the treatment of HER2-positive breast cancer in the South Indian population.<h4>Methods</h4>This retrospective audit included patients with locally advanced HER2-positive breast cancer who received neoadjuvant chemotherapy with a short course of trastuzumab (nine weekly doses) following the FinHer protocol in a resource-limited setting. The gene discussed is ERBB2; the disease is breast carcinoma.